Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

33%(1 trials)

Phase Distribution

Ph phase_2

25%

Ph phase_1

25%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 31 (33.3%)

Trials by Status

completed375%

withdrawn125%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

NCT06014853

completedphase_3

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

NCT04887506

completedphase_2

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

NCT04862091

withdrawn

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

NCT03325127

Clinical Trials (4)

Showing 4 of 4 trials

NCT06014853Phase 1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects

Completed

NCT04887506Phase 3

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Completed

NCT04862091Phase 2

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Completed

NCT03325127

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4